MSN labs on Friday announced the launch of an anti-fungal drug Posaconazole meant to treat black fungus (mucormycosis) patients in India. This comes as several states in the country have declared black fungus as an epidemic.
In a company press release, MSN said the product has been launched under the brand name PosaOne as 100 mg Delayed Release tablets and 300 mg injections, respectively. The drug has also been approved by the Drug Controller General of India (DGCI), the press release said.
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients.
Mucormycosis is a fungal infection that mainly affects people who are on medication for other health problems that reduce their ability to fight environmental pathogens.